Christopher Causey Sells 1,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $510.00, for a total value of $510,000.00. Following the transaction, the director directly owned 4,190 shares in the company, valued at $2,136,900. This trade represents a 19.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Christopher Causey also recently made the following trade(s):

• On Friday, January 2nd, Christopher Causey sold 1,000 shares of United Therapeutics stock. The stock was sold at an average price of $500.01, for a total value of $500,010.00.

United Therapeutics Trading Up 0.2%

NASDAQ:UTHR opened at $503.69 on Thursday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $519.99. The company has a 50-day moving average price of $482.44 and a 200-day moving average price of $399.49. The stock has a market cap of $21.69 billion, a price-to-earnings ratio of 19.09, a P/E/G ratio of 2.61 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same period last year, the business posted $6.39 earnings per share. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on UTHR shares. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. HC Wainwright boosted their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a report on Wednesday, October 29th. Finally, UBS Group upped their target price on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research note on Tuesday. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $509.50.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently bought and sold shares of UTHR. Chung Wu Investment Group LLC purchased a new stake in United Therapeutics in the second quarter worth about $29,000. WealthCollab LLC grew its stake in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Wilmington Savings Fund Society FSB raised its stake in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the period. Finally, Abich Financial Wealth Management LLC purchased a new position in United Therapeutics during the third quarter valued at approximately $44,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analyst upgrades and raised price targets reinforce bullish outlook (consensus “Moderate Buy” and ~$505–509 consensus targets); several firms have lifted targets and reiterated buys, supporting demand. MarketBeat UTHR coverage
• Positive Sentiment: Recent quarterly results: EPS beat estimates ($7.16 vs. $6.89) with a high net margin (~40.7%) and ROE near 19%, underscoring strong profitability that investors favor. Earnings summary
• Positive Sentiment: Institutional ownership remains very high (~94%) and some funds increased positions recently, which can support price stability and amplify analyst-driven buying. Institutional holdings
• Neutral Sentiment: Sector comparison piece highlights UTHR vs. Zoetis (ZTS) for value investors — useful for positioning but not an immediate catalyst. Zacks comparison article
• Neutral Sentiment: Market write-ups (e.g., Yahoo Finance) discuss UTHR’s attractive financial prospects; informative for longer-term investors but not an immediate price driver. Yahoo Finance analysis
• Negative Sentiment: Significant insider selling by COO Michael Benkowitz: large block sales on Jan. 5 totaling tens of thousands of shares (multiple filings; combined value in the millions), which can be viewed negatively by the market. Benko witz SEC filing
• Negative Sentiment: Director-level sales: Christopher Causey sold 1,000 shares (around $500 avg), and Jan Malcolm sold multiple small lots (50 shares each recently). Repeated director sales may create near-term selling pressure or signal portfolio rebalancing. Causey SEC filing Malcolm SEC filing

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.